DB:2FV

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. More Details


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has ScandiDos's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2FV has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-6.8%

2FV

-0.3%

DE Medical Equipment

-4.1%

DE Market


1 Year Return

-32.4%

2FV

20.7%

DE Medical Equipment

4.2%

DE Market

Return vs Industry: 2FV underperformed the German Medical Equipment industry which returned 20.7% over the past year.

Return vs Market: 2FV underperformed the German Market which returned 4.2% over the past year.


Shareholder returns

2FVIndustryMarket
7 Day-6.8%-0.3%-4.1%
30 Day-7.2%-2.2%-2.9%
90 Day7.9%-0.8%2.7%
1 Year-32.4%-32.4%22.4%20.7%6.7%4.2%
3 Yearn/a158.1%152.2%1.9%-6.4%
5 Yearn/a269.5%254.2%32.5%14.4%

Price Volatility Vs. Market

How volatile is ScandiDos's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ScandiDos undervalued compared to its fair value and its price relative to the market?

2.55x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 2FV's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 2FV's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 2FV is unprofitable, so we can't compare its PE Ratio to the DE Medical Equipment industry average.

PE vs Market: 2FV is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2FV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2FV is good value based on its PB Ratio (2.5x) compared to the DE Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is ScandiDos forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ScandiDos has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has ScandiDos performed over the past 5 years?

1.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2FV is currently unprofitable.

Growing Profit Margin: 2FV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2FV is unprofitable, but has reduced losses over the past 5 years at a rate of 1.9% per year.

Accelerating Growth: Unable to compare 2FV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2FV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.8%).


Return on Equity

High ROE: 2FV has a negative Return on Equity (-28.39%), as it is currently unprofitable.


Next Steps

Financial Health

How is ScandiDos's financial position?


Financial Position Analysis

Short Term Liabilities: 2FV's short term assets (SEK38.0M) exceed its short term liabilities (SEK24.7M).

Long Term Liabilities: 2FV has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 2FV's debt to equity ratio (3.8%) is considered satisfactory.

Reducing Debt: 2FV's debt to equity ratio has reduced from 18.2% to 3.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2FV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 2FV has less than a year of cash runway if free cash flow continues to grow at historical rates of 2% each year.


Next Steps

Dividend

What is ScandiDos's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2FV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2FV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2FV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2FV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2FV's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

Gustaf Piehl (42 yo)

no data

Tenure

Mr. Gustaf Piehl serves as Chief Executive Officer at ScandiDos AB (publ) since September 2020. He Gustaf has many years of experience in the radiation therapy industry after holding a number of different ...


Leadership Team

NamePositionTenureCompensationOwnership
Gorgen Nilsson
Technical Managerno datakr1.99mno data
Ingemar Wiberg
Deputy CEO & Director5.67yrskr1.23mno data
Gustaf Piehl
Chief Executive Officerno datano datano data
Catarina Arkebäck
Chief Financial Officer8.67yrsno datano data
Anders Adolfson
Marketing Manager3.92yrsno datano data
Peter Reinli
Vice President of Sales1.08yrsno datano data

6.3yrs

Average Tenure

58.5yo

Average Age

Experienced Management: 2FV's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ingemar Wiberg
Deputy CEO & Director5.67yrskr1.23mno data
Christer Fåhraeus
Director1.67yrskr50.00kno data
Tom Sundelin
Directorno datakr100.00kno data
Olof Sandén
Chairman of the Board5.67yrskr250.00kno data
Sten Hornsleth
Director1.67yrskr50.00kno data

3.7yrs

Average Tenure

58yo

Average Age

Experienced Board: 2FV's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ScandiDos AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ScandiDos AB (publ)
  • Ticker: 2FV
  • Exchange: DB
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr117.743m
  • Listing Market Cap: kr11.301m
  • Shares outstanding: 41.46m
  • Website: https://scandidos.com

Number of Employees


Location

  • ScandiDos AB (publ)
  • Uppsala Science Park
  • Uppsala
  • 751 83
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SDOSOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKApr 2014
2FVDB (Deutsche Boerse AG)YesShare CapitalDEEURApr 2014

Biography

ScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. The company offers Delta4 Family soluti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/24 04:06
End of Day Share Price2020/09/23 00:00
Earnings2020/04/30
Annual Earnings2020/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.